Stromal Cell-Derived Factor 1 Polymorphism in Retinal Vein Occlusion

Szigeti, A [Szigeti, Andrea (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K); Ecsedy, M [Ecsedy, Mónika (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K); Schneider, M [Schneider, Miklós (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K); Lenart, L [Lénárt, Lilla (nephrológia), szerző] MTA-SE Lendület Diabétesz Kutatócsoport (SE / AOK / K / ISZGYK); Lesch, B [Lesch, Balázs (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K); Nagy, ZZ [Nagy, Zoltán Zsolt (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K); Fekete, A [Fekete, Andrea (nefrológia, gyerm...), szerző] MTA-SE Lendület Diabétesz Kutatócsoport (SE / AOK / K / ISZGYK); Recsan, Z [Récsán, Zsuzsanna (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K)

Angol nyelvű Tudományos Szakcikk (Folyóiratcikk)
Megjelent: PLOS ONE 1932-6203 11 (11) Paper: e0166544 , 11 p. 2016
  • Pedagógiai Tudományos Bizottság: A
  • Szociológiai Tudományos Bizottság: A nemzetközi
  • SJR Scopus - Agricultural and Biological Sciences (miscellaneous): Q1
    BACKGROUND: Stromal cell-derived factor 1 (SDF1) has crucial role in the regulation of angiogenesis and ocular neovascularisation (NV). The purpose of this study was to evaluate the association between SDF1-3'G(801)A polymorphism and NV complications of retinal vein occlusion (RVO). METHODS: 130 patients with RVO (median age: 69.0, range 35-93 years; male/female- 58/72; 55 patients had central RVO, 75 patients had branch RVO) were enrolled in this study. In the RVO group, 40 (30.8%) patients were diagnosed with NV complications of RVO and 90 (69.2%) patients without NVs. The median follow up period was 40.3 months (range: 18-57 months). The SDF1-3'G(801)A polymorphism was detected by PCR-RFLP. Allelic prevalence was related to reference values obtained in the control group consisted of 125 randomly selected, age and gender matched, unrelated volunteers (median age: 68.0, range 36-95 years; male/female- 53/72). Statistical analysis of the allele and genotype differences between groups (RVO patients vs controls; RVO patients with NV vs RVO patients without NV) was determined by chi-squared test. P value of <0.05 was considered statistically significant. RESULTS: Hardy-Weinberg criteria was fulfilled in all groups. The SDF1-3'G(801)A allele and genotype frequencies of RVO patients were similar to controls (SDF1-3'A allele: 22.3% vs 20.8%; SDF1-3'(801)AA: 5.4% vs 4.8%, SDF1-3'(801)GG: 60.8% vs 63.2%). The frequency of SDF1-3'(801)AA and SDF1-3'(801)GA genotypes, as well as the SDF1-3'(801)A allele frequency were higher in RVO patients with NV versus in patients without NV complication (SDF1-3'(801)AA+AG genotypes: 57.5% vs 31.1%, p = 0.008; SDF1-3'(801)A allele: 35.0% vs 16.7%, p = 0.002) or versus controls (SDF1-3'(801)AA+AG genotypes 57.5% vs 36.8%, p = 0.021; SDF1-3'(801)A allele: 35.0% vs 20.8% p = 0.01). Carrying of SDF1-3'(801)A allele increased the risk of neovascularisation complications of RVO by 2.69 (OR, 95% CI = 1.47-4.93). CONCLUSION: These findings suggest that carrying SDF1-3'(801)A allele plays a role in the development of neovascular complications in retinal vein occlusion.
    Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
    2021-05-09 04:33